deltatrials
Unknown PHASE1 INTERVENTIONAL 11-arm NCT03657381

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 by Advanced Tumor Subjects

Sponsor: Shandong New Time Pharmaceutical Co., LTD

Conditions Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
Interventions Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Updated 8 times since 2018 Last updated: Oct 19, 2020 Started: Mar 1, 2019 Primary completion: Feb 8, 2021 Completion: Oct 8, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma and is currently ongoing. Shandong New Time Pharmaceutical Co., LTD leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2018 – ~May 2019 · 7 months · monthly snapshotNot Yet Recruiting~May 2019 – ~Apr 2020 · 11 months · monthly snapshotRecruiting~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotRecruiting~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshotRecruiting~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Nov 2022 — Jul 2024 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  4. Jan 2021 — Nov 2022 [monthly]

    Recruiting PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

▶ Show 3 earlier versions

  1. Apr 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  2. May 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  3. Oct 2018 — May 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shandong New Time Pharmaceutical Co., LTD
Data source: Shandong New Time Pharmaceutical Co., LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations